
PANCREATIC CANCER ACTION NETWORK

Taking bold action to improve the lives of pancreatic cancer patients



## **Improve Patient Outcomes**



As reported on the indicated year by

American Cancer Society, Cancer Facts and Figures 1999-2022, SEER-9 and SEER-18 Databases

# Our approach:

Fig pa ca ev

#### Research



**Government Advocacy** 



**PanCAN Patient Services** 



**Community** 



## **Including \$25M in 2022!**



GRANTS PROGRAM



KNOW YOUR TUMOR®



PATIENT REGISTRY



PRECISION PROMISE SM



EARLY DETECTION INITIATIVE



SPARK
HEALTH DATA
PLATFORM

## PRECISION PROMISE:

ADAPTIVE - LEARN AS YOU GO

PLATFORM - MULTIPLE THERAPIES
TESTED SIMULTANEOUSLY

TRIAL - PanCAN IS THE SPONSOR

Open at >20 sites



ACTION NETWORK

#### THE GRANTS PROGRAM

**Unmet need:** How can we incentivize Pharma/Biotech to invest in a pancreatic cancer indication for their new therapies and build the Precision Promise pipeline?

Pancreatic Cancer often not a priority by Pharma/Biotech due to high risk and market size

Early-Stage development decisions continue to favor cancers outside of pancreatic cancer

Need to accelerate early-stage development by directly funding Pharma/Biotech



- Up to \$5M in support to offset cost of testing approach in an early-stage (Phase I/II) PDAC clinical trial
- Company holds the IND and retains all IP rights
- Focus: to accelerate the development of therapeutic strategies that address vulnerabilities found in a significant portion (>20%) of pancreatic ductal adenocarcinoma (PDAC) cases
  - 2022 major priority: therapies that target KRAS G12D and/or G12V mutations, combinations of inhibitors of downstream pathways of KRAS shown to display synthetic lethality, or metabolic vulnerabilities identified as being major contributors to PDAC growth and survival
  - 2023 major priority: strategies that reverse the immunosuppressive tumor microenvironment and/or help achieve a robust immune response
  - Other approaches considered and evaluated based on quality and abundance of supporting evidence



Ε

## Criteria

A legal U.S. entity that is a pharmaceutical or biotechnology company Principal
Investigator must
be employed by or
represent the
company

PI or co-PI team must include a MD with experience in clinical trials Suitability for a successful candidate to advance into PanCAN's Precision Promise<sup>SM</sup> study



## En

## **Key Decision Makers**

Scientific review Letters of Intent Scientific experts received NIH scale **Applications Business review** received Skipper + PanCAN **Business Development Administrative** Overall Score 1-100 review Eligibility check Legal diligence

PanCAN Legal due

diligence for red flags

Simultaneous, independent

#### **Programmatic Review Committee**

- Initial scoring: Strong fund to strong not fund
- Teleconference discussion
- Rescoring
- PanCAN staff & Skipper BioMed team to answer questions, present any updates
- Committee:
  - Board of Director members
  - Patient Research Advocate
  - Former and current Pharma and **Biotech Execs**
  - Clinical Trialists

**PanCAN** 

#### Ranked applications

- Fully fund
- Partially fund
- Assist in other ways
- Execute contracts


PANCRE ITIC CANCER **ACTION** 

**NETWORK** 

Zoom call

### **WORKING GROUP**

- Unlikely the trial will be the last one ever
- How can we make it better in the future?
  - What worked?
  - What didn't work?
  - Does it work best on a subset of patients?
  - What other combinations would be better?
- 5 investigators chosen for their expertise
  - Submitted proposals
  - Proposals modified and approved for funding through our flexible Catalyst Award program
  - \$1.5M total
- PanCAN, TAA recipient, and Precision Promise academic investigator lead Working Group
  - Monthly 90-minute calls for progress, collaboration



#### Award to Pharma/Biotech company

Peer Review Process – inclusion of PanCAN Board of Directors with expertise in drug development and venture capital, as well as partnership with Skipper BioMed to develop business scoring tool and conduct business due diligence review

Correlative/Ancillary studies to address pathway assumptions in main clinical trial

Outcomes expected to advance new treatments for pancreatic cancer in the near term







Readiness to move on to later stage development in Precision Promise<sup>SM</sup> clinical trial



#### **Long Term Outcome**:

Successful transition to Phase III of Precision Promise<sup>SM</sup> and approval by the FDA



- Robust appetite for award mechanism based on number of companies expressing interest
- Good to build in LOI process to prepare for peer review
- There is a need to incorporate expertise that understands the business of Pharma/Biotech entities
- Can influence Pharma/Biotech via such a funding mechanism by focusing them on certain types of research (e.g., immunotherapy studies)



## Questions?